Targeting TGF-beta signaling to treat osteosarcoma
Official title: c-Myc regulation by TGF-beta signaling as a therapeutic target in Osteosarcoma
Funded at Case Western Reserve University · NIH-10991388 · Data updated 2026-11-12
This study is looking at how a new drug called TEW-7197 can help treat osteosarcoma, a type of bone cancer that can spread to the lungs, by blocking a specific signaling pathway, and it aims to find out if this can improve the way the cancer grows and how the immune system responds.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $80,500 |
| NIH project number | 5R03CA273468-02 |
| Project ID | NIH-10991388 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and young adults diagnosed with osteosarcoma, particularly those with pulmonary metastases.
✕Less likely to help
Patients with non-cancerous bone conditions or those whose osteosarcoma is not metastatic may not benefit from this research.
What this research studies
This research investigates the role of TGF-beta signaling in osteosarcoma, a type of bone cancer that often spreads to the lungs. The study aims to evaluate the effects of a new drug, TEW-7197, which inhibits TGF-beta signaling, on the growth of osteosarcoma cells both in laboratory settings and in animal models. By understanding how this drug can alter the tumor environment and immune responses, the research seeks to improve treatment outcomes for patients with pulmonary metastatic osteosarcoma.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced osteosarcoma, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in targeting TGF-beta signaling in other cancers, indicating potential for success in this novel approach for osteosarcoma.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Choi, Sung Hee — Case Western Reserve University
- Study coordinator: Choi, Sung Hee
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.